GLP-1RAs and Advanced Liver Outcomes in Type 2 Diabetes: A Systematic Review

A systematic review and meta-analysis of real-world cohort studies investigating the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and advanced liver outcomes in adults with type 2 diabetes. The work by Jing-Hong Hu, published on figshare in 2026, includes 12 eligible comparative studies, with a primary pooled hazard ratio estimate of 0.85 for serious liver events. The evidence is rated as very low certainty due to the observational nature of the included studies.

Use Cases

• Conducting secondary meta-analyses based on the pooled hazard ratios and confidence intervals reported.
• Identifying gaps in real-world evidence for drug safety outcomes based on the review's inclusion criteria and study limitations.
• Designing observational studies on drug effectiveness using the described active-comparator and outcome-family stratification methods.

Strengths

• Includes a predefined analysis stratum focusing on active-comparator designs.
• Reports specific statistical results, including a primary Hartung-Knapp interval (HR 0.85, 95% CI 0.74–0.98) and a secondary REML estimate.
• Provides a systematic review registration identifier (CRD420261299499) for transparency.

Limitations

• The dataset is a 1019.8 KB DOCX document; the underlying tabular meta-analysis data is not provided as a separate, machine-readable file.
• Column-level documentation for any potential supplementary data is absent; field semantics must be inferred from the document text.
• The description notes a 'very low' certainty of evidence due to observational study designs, residual confounding, and varied outcome definitions.

Provenance

Source

figshare, authored by Jing-Hong Hu.

Collection Method

Systematic review and exploratory meta-analysis of peer-reviewed comparative real-world cohort studies identified via PubMed/MEDLINE and Embase.

Time Range

Literature search updated through 25 April 2026.

Freshness

Last updated 2026-06-02 04:21:25.